fda bpc-157 warning letter peptide panel narrowly backs unapproved drugs – NBC4 Washington fda warning letter bpc-157 unapproved

Heres what researchers have learned recently about neurokinin B and hot flashes: Neurokinin B was identified in a genome-wide association study as the only gene that plays a significant role in hot flashes (vasomotor symptoms).[ref] Another strong indication that neurokinin B is integral to hot flashes is that when neurokinin B is given to young women by IV, it triggers hot flashes in 80% of the women.[ref] A placebo-controlled clinical trial of an NK3R (neurokinin B receptor) antagonist drug, which blocks the neurokinin B receptor, showed that it quickly reduced hot flash frequency by more than half compared to a placebo.[ref][ref] The emerging picture is that hot flashes involve body temperature mechanisms in the hypothalamus that are affected by estrogen and neurokinin B, which in turn affect FSH and LH levels

The regulatory picture around compounding continues to evolve, so its worth checking current status with a prescribing physician

Healthcare providers must keep a close eye on patients getting high-dose B12 therapy to handle any side effects well

It helps make red blood cells, keeps nerves working, and aids in DNA creation